New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
[OncoTargets and Therapy] Evidence increasingly suggests that pembrolizumab has a significant role in first- and second-line therapy for NSCLC. This review presents the results of previous and ongoing studies and discusses biomarkers that can potentially identify eligible candidates for treatment with the PD-L1 inhibitor.
